Table 3 Total adverse events
From: Assessing the effectiveness of rapamycin on angiomyolipoma in tuberous sclerosis: a two years trial
No of patients (%) / No of events | |
|---|---|
(N=17) / (N=36) | |
Gastrointestinal | |
Oral mucositis | 5 (29.4%) / 7 |
Diarrhoea | 3 (17.6%) / 5 |
Skin-related | |
Acneiform rash | 2 (11.8%) / 2 |
Exacerbation of erythema nodosum | 1 ( 5.9%) / 2 |
nodosum | |
Metabolic or laboratory | |
Hypertriglyceridemia | 5 (29.4%) / 5 |
Microcytosis and hypochromia | 3 (17.6%) / 3 |
Gynaecological | |
Menstruation disturbances | 3 (17.6%) / 3 |
Renal | |
Nephrotic range proteinuria | 1 ( 5.9%) / 1 |
MAU <2 x ULN | 3 (17.6%) / 3 |
MAU 2–3 x ULN | 2 (11.8%) / 2 |
MAU 3 x ULN | 2 (11.8%) / 2 |
Acute pyelonephritis | 1 ( 5.9%) / 1 |